ACTRN12610000921088招募中未知
A Feasibility study of 200 patients with non-valvular atrial fibrillation and an ongoing indication for anticoagulation to prevent embolic stroke that will have left atrial appendage closure with the Coherex Left Atril Appendage Occlusion System to evaluate the safety and efficacy of the device in preventing embolic stroke.
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.At least 18 years of age.
- •2.Diagnosis of paroxysmal, persistent, or permanent non-valvular atrial fibrillation.
- •3.Indicated for long-term anticoagulation therapy including patients on anticoagulants and patients with a contraindication to anticoagulation. The first 30 patients must have a contraindication to anticoagulation.
- •4.Eligible for cessation of anticoagulation therapy if the LAA is sealed (i.e., the patient has no other condition requiring anticoagulation therapy).
- •5.Calculated CHADS score = 1.
- •6.Willingness to participate in the required follow-up visits and tests.
- •7.Willingness of patient or legal representative to provide written informed consent.
- •8.Female subjects of child-bearing potential must have a negative serum pregnancy test within 7 days prior to the index procedure, and must be willing to use reliable contraception methods for one year post-procedure.
排除标准
- •1.Known contraindication and/or allergy to aspirin, clopidogrel, IV contrast, or nickel.
- •2.Extensive congenital cardiac anomalies, which can only be adequately repaired by cardiac surgery.
- •3.Stroke or transient ischemic attack (TIA), as diagnosed by a neurologist, within the past 30 days. Patients with a history of stroke or TIA will not be allowed to enroll until 30 cases have been completed.
- •4.New York Heart Association Class IV Congestive Heart Failure, defined as patients with severe physical limitations and symptoms even while at rest.
- •5.Myocardial infarction within the past three months.
- •6.Sepsis within one month prior to implantation or any systemic infection that cannot be successfully treated prior to device placement.
- •7.Presence of an atrial septal defect, atrial septal repair, or atrial septal closure device.
- •8.Female subjects who may be pregnant or are planning on becoming pregnant in the next year.
- •9.Cardioversion or ablation procedure planned in conjunction with or within 30 days after placement of the Coherex Left Atrial Appendage Occlusion System.
- •10.Cardiac transplant or mechanical valve.
- •11.Symptomatic carotid artery disease.
- •12.Any medical disorder or psychiatric illness that would interfere with successful completion of the study as determined by the investigator.
- •13. Conditions other than atrial fibrillation requiring long-term warfarin therapy.
- •14.Resting heart rate > 110 beats per minute (bpm).
- •15.A single episode of transient atrial fibrillation.
- •16.Thrombocytopenia (<50,000 platelets/mm3), thrombocythemia (>700,000 platelets/mm3), leucopenia (white blood cell count < 3,000 cells/mm3), or anemia (hemoglobin concentration < 10 gram per deciliter [g/dl]).
- •17.Currently participating in an investigational drug or another device trial that has not completed the primary endpoint or that clinically interferes with the current trial endpoints. (Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.)
- •18.Any condition that would reduce life expectancy to less than two years from the date of the index procedure.
- •Echocardiographic criteria for exclusion:
- •1.Left ventricular ejection fraction (LVEF) < 30%.
- •2.Mitral valve stenosis < 1.5 cm2 or any stenosis consistent with rheumatic valvular disease.
- •3.Pericardial effusion > 5 mm pre-procedure.
- •4.Evidence of intracardiac thrombus visualized on TEE.
- •5.Presence of a patent foramen ovale (PFO) that demonstrates a large shunt and/or atrial septal aneurysm with > 10 mm excursion.
- •6.Cardiac tumor.
研究者
相似试验
招募中
不适用
Brain Pulse Monitoring Study in patients with or at risk of developing stroke to provide earlier detection of strokeNeurological - Other neurological disordersStroke - HaemorrhagicStroke - IschaemicStrokeACTRN12622001320741Cyban Pty Ltd100
招募中
不适用
COHEREX-EU:A Multi-Center Study to Evaluate the Safety and Efficacy of the Coherex FlatStent Patent Foramen Ovale(PFO) Closure SystemSymptomatic Patent Foramen OvaleThe Coheres FlatStent Patemnt Foramen Oveale (PFO) Closure System will be implanted when closure of a Patent Foramen Ovale is clinically indicated. Each patient who receives an implant will be followed for six months after the the FlatStent is implanted. Enrollment will continue for six months or until 50 patients have been enrolled.Cardiovascular - Other cardiovascular diseasesACTRN12607000623493Coherex Medical Inc.50
进行中（未招募）
不适用
A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and RituximabTreatment of patients with newly diagnosed splenic marginal non Hodgkin lymphomaMedDRA version: 9.1Level: LLTClassification code 10062113Term: Splenic marginal zone lymphomaEUCTR2005-000693-45-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
招募中
不适用
Characterization of patients on non invasive ventilation in a german respiratory care unitJ96.11J44Other chronic obstructive pulmonary diseaseDRKS00008759ungenklinik Köln-MerheimKliniken der Stadt Köln gGmbH66
已完成
不适用
A prospective observational study of patients with advanced cancer for the evaluation of checkpoint inhibitor-associated cardiovascular immune-related adverse eventsAdvanced non-small-cell lung cancer and advanced gastric cancer which are indications for anti-cytotoxic T-lymphocyte-associated antigen-4, anti-programmed death-1, and anti-programmed death-ligand 1 antibodies.JPRN-UMIN000032729Frontline Immunotherapy Team, Sendai Kousei Hospital129